Immunicum AB (publ) today announced that the first patient has been enrolled in the Phase I ALISON clinical study evaluating DCP-001, the Company’s lead cancer relapse vaccine candidate, in High-Grade ...
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced the presentation of new clinical data from the Phase 1 ALISON ...
Immunicum AB (publ) today announced that the first patient has been enrolled in the Phase I ALISON clinical study evaluating DCP-001, the Company’s lead cancer relapse vaccine candidate, in High-Grade ...
ImmunicumAnnounces Enrollment of First Patient in Phase IALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer - First study evaluating cancer relapse vaccine candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback